Trials / Completed
CompletedNCT04159766
A Study With NLY01 in Subjects With Type 2 Diabetes
A Phase 2a Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NLY01, a PEGylated Exenatide, When Administered as a Single Dose in Subjects With Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Neuraly, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2a study designed to assess the effect of NLY01 in patients with type 2 diabetes. Patients will be monitored for safety, pharmacokinetics, and pharmacodynamic effects on glycemic control.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NLY01 | NLY01, a PEGylated form of the anti-diabetic peptide exenatide |
| DRUG | Placebo | normal saline |
Timeline
- Start date
- 2019-10-16
- Primary completion
- 2020-12-04
- Completion
- 2020-12-04
- First posted
- 2019-11-12
- Last updated
- 2021-03-02
Locations
2 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT04159766. Inclusion in this directory is not an endorsement.